Cardiac production of B-type natriuretic peptide is inversely related to the plasma level of free fatty acids in obese individuals - Possible involvement of the insulin resistance -

Endocrine Journal

Volumn 60, Issue 1, 2013, Pages 87-95

  Mizuno, Yuji ^a   Harada, Eisaku ^a   Katoh, Daisuke ^a,b   Kashiwagi, Yusuke ^a,b   Morikawa, Yoshinobu ^a,c   Nakagawa, Hitoshi ^a,c   Yoshimura, Michihiro ^b   Saito, Yoshihiko ^c   Yasue, Hirofumi ^a  

^a Kumamoto Kinoh Hospital   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

B type natriuretic peptide; Free fatty acids; Insulin resistance; Obesity

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; FATTY ACID DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGE; AGED; AORTA ROOT; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY SINUS; CORRELATION COEFFICIENT; FATTY ACID BLOOD LEVEL; FEMALE; HEART CATHETERIZATION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODYNAMIC PARAMETERS; HUMAN; INDEPENDENT VARIABLE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; PEPTIDE SYNTHESIS; WAIST CIRCUMFERENCE;

ADULT; AGED; CARDIAC CATHETERIZATION; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INSULIN RESISTANCE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OBESITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84873519445     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ12-0239     Document Type: Article

References (46)

1. Munagala VK, Burnett JC Jr, Redfield MM (2004) The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 29: 707-769.
2. Gardner DG, Chen S, Glenn DJ, Grigsby CL (2007) Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 49: 419-426.
3. Kuwahara K, Nakao K (2010) Regulation and significance of atrial and brain natriuretic peptides as cardiac hormones. Endocr J 57: 555-565.
4. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, et al. (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87: 1402-1412.
5. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, et al. (1993) Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87: 464-469.
6. Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, et al. (1996) Superiority of brain natri uretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28: 988-994.
7. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, et al. (1997) Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96: 509-516.
8. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, et al. (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345: 1014-1021.
9. Suzuki S, Yoshimura M, Nakayama M, Mizuno Y, Harada E, et al. (2004) Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. Circulation 110: 1387-1391.
10. Huss JM, Kelly DP (2005) Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 115: 547-555.
11. Neubauer S (2007) The failing heart-an engine out of fuel. N Engl J Med 356: 1140-1151.
12. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90: 207-258.
13. Taegtmeyer H, Sen S, Vela D (2010) Return to the fetal gene program: a suggested metabolic link to gene expression in the heart. Ann N Y Acad Sci 1188: 191-198.
14. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, et al. (2005) Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112: 2163-2168.
15. Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS (2006) B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 152: 1071-1076.
16. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, et al. (2007) Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 115: 1345-1353.
17. Sugisawa T, Kishimoto I, Kokubo Y, Makino H, Miyamoto Y, et al. (2010) Association of plasma B-type natriuretic peptide levels with obesity in a general urban Japanese population: the Suita Study. Endocr J 57: 727-733.
18. Dessì-Fulgheri P, Sarzani R, Tamburrini P, Moraca A, Espinosa E, et al. (1997) Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens 15: 1695-1699.
19. Dessì-Fulgheri P, Sarzani R, Rappelli A (1998) The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. J Nephrol 11: 296-299.
20. Date T, Yamane T, Yamashita S, Matsuo S, Matsushima M, et al. (2012) Paradoxical clearance of natriuretic peptide between pulmonary and systemic circulation: a pulmonary mechanism of maintaining natriuretic peptide plasma concentration in obese individuals. J Clin Endocrinol Metab 97: E14-21.
21. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, et al. (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90: 195-203.
22. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, et al. (2005) Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440-1463.
23. Nishikimi T, Minamino N, Ikeda M, Takeda Y, Tadokoro K, et al. (2010) Diversity of molecular forms of plasma brain natriuretic peptide in heart failure-different proB-NP-108 to BNP-32 rations in atrial and ventricular overload. Heart 96: 432-439.
24. Shimizu S, Tani Y, Yamada H, Tabata M, Murachi T (1980) Enzymatic determination of serum-free fatty acids: a colorimetric method. Anal Biochem 107: 193-198.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
26. Katz MH (2011) Setting up a multivariable analysis. In: Katz MH, Multivariable Analysis. Cambridge University Press, New York: 97-102.
27. Banke NH, Wende AR, Leone TC, O'Donnell JM, Abel ED, et al. (2010) Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARα. Circ Res 107: 233-241.
28. Haemmerle G, Moustafa T, Woelkart G, Büttner S, Schmidt A, et al. (2011) ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med 17: 1076-1085.
29. Smith J, Su X, El-Maghrabi R, Stahl PD, Abumrad NA (2008) Opposite regulation of CD36 ubiquitination by fatty acids and insulin: effects on fatty acid uptake. J Biol Chem 283: 13578-13585.
30. Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, et al. (2011) Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab 96: 3242-3249.
31. Nakatsuji H, Kishida K, Funahashi T, Nakagawa T, Shimomura I (2012) Hyperinsulinemia correlates with low levels of plasma B-type natriuretic peptide in Japanese men irrespective of fat distribution. Cardiovasc Diabetol 11: 22.
32. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, et al. (2002) The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109: 121-130.
33. Duncan JG, Bharadwaj KG, Fong JL, Mitra R, Sambandam N, et al. (2010) Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-α transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferatoractivated receptor-α activators. Circulation 121: 426-435.
34. Liang F, Wang F, Zhang S, Gardner DG (2003) Peroxisome proliferator activated receptor (PPAR) α agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology 144: 4187-4194.
35. Luo Y, Jiang C, Belanger AJ, Akita GY, Wadsworth SC, et al. (2006) A constitutively active hypoxia-inducible factor-1alpha/VP16 hybrid factor activates expression of the human B-type natriuretic peptide gene. Mol Pharmacol 69: 1953-1962.
36. Weidemann A, Klanke B, Wagner M, Volk T, Willam C, Wiesener MS, Eckardt KU, Warnecke C (2008) Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1alpha, is a direct and sufficient stimulus for brain-type natriuretic peptide induction. Biochem 409: 233-242.
37. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E (2002) Insulin stimulates hypoxiainducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 277: 27975-27981.
38. Demidenko ZN, Blagosklonny MV (2011) The purpose of the HIF-1/PHD feedback loop: to limit mTOR-induced HIF-1α. Cell Cycle 10: 1557-1562.
39. Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, et al. (2009) Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 58: 2880-2892.
40. Choquet H, Cavalcanti-Proença C, Lecoeur C, Dina C, Cauchi S, et al. (2009) The T-381C SNP in BNP gene may be modestly associated with type 2 diabetes: an updated meta-analysis in 49 279 subjects. Hum Mol Gene 18: 2495-2501.
41. Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, et al. (2008) Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab 19: 130-137.
42. Szczepaniak LS, Victor RG, Orci L, Unger RH (2007) Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res 101: 759-767.
43. Brindley DN, Kok BP, Kienesberger PC, Lehner R, Dyck JR (2010) Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization. Am J Physiol Endocrinol Metab 298: E897-908.
44. Kadowaki T, Sekikawa A, Murata K, Maegawa H, Takamiya T, et al. (2006) Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a populationbased study. Int J Obes (Lond) 30: 1163-1165.
45. Sniderman AD, Bhopal R, Prabhakaran D, Sarrafzadegan N, Tchernof A (2007) Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. Int J Epidemiol 36: 220-225.
46. Imamura S, Kobayashi J, Nakajima K, Sakasegawa S, Nohara A, et al. (2008) A novel method for measuring human lipoprotein lipase and hepatic lipase activities in post heparin plasma. J Lipid Res 49: 1431-1437.